Mexico: Collaboration and Digitization as Keys to Growth in Healthcare

Mexico is at a 'decisive point' for the growth of the pharmaceutical industry. This was stated by Javier Dávila, General Director of Planning and Evaluation of the Ministry of Economy (SE), at the forum 'Medical Innovation: Transforming Patients' Lives,' organized by Bayer at the National Medical Center 'XXI Century' of the Mexican Social Security Institute. Dávila emphasized that timely detection is crucial to reduce mortality. Legislators and authorities agreed on the need to modernize the regulatory framework and digitize processes to foster innovation. The forum 'Medical Innovation: Transforming Patients' Lives' made it clear that Mexico has a real opportunity to transform its healthcare system through innovation and collaboration. With a coordinated approach, the country can accelerate access to innovative therapies and improve the quality of life for millions of patients. Several relevant topics for the sector were addressed during the event. Chronic Kidney Disease: It is estimated that 10 to 12 million Mexicans suffer from this disease, but only 60,000 receive treatment. Early detection and an increase in nephrologists are urgent. Hemophilia: Innovation in treatments has significantly improved the quality of life for patients, allowing for home treatments that require only a weekly application. Adolescent Pregnancy: Prevention requires sexual health education and access to contraceptives. This positions Mexico as a key market for research in critical areas such as cardiology, urology, and mental health. Collaboration and digitization as keys to growth in Mexico. The pharmaceutical industry in Mexico is at a crucial crossroads, with the potential to multiply its growth by three to four times. Among the priority actions mentioned were: digitization of processes, parallel approvals with international agencies, and modernization of the Mexican Institute of Industrial Property (IMPI). 'If we continue with this policy, the industry can grow three to four times,' Dávila assured. Meanwhile, Daniel Londero, General Director of Bayer Mexico, highlighted that the company is conducting over 30 clinical trials and evaluating another 40 in the country. Carlos Flores Zarza, Coordinator of Administrative Services of the IMSS, emphasized that innovation is essential to improve medical care. Bayer is also working on advanced therapies that could cure currently untreatable diseases. The forum began with a message from the Lic. Adolescents can request long-acting devices for free. Prostate Cancer: Only 25% of cases are diagnosed on time.